Kelly M. Brunk, PharmD, BCOP

Bispecific therapies require clearer terminology to improve safety and communication.

Current guideline recommendations include various combinations of targeted therapy with immunotherapy.

In June 2020, the FDA granted a fast track designation to fruquintinib for patients with mCRC previously treated with other therapies.